BioMar Group A/S – Trademark Portfolio

Entity Type: 99

BioMar Group A/S holds 5 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 31 (Natural Agricultural Products) — 5 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include LARVIVA, SMARTCARE, and BLUE IMPACT. The owner is based in Aarhus.

Værkmestergade 25, 6.

Aarhus 8000AarhusC , DK

5 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

BioMar Group A/S's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

31
Natural Agricultural Products (5 filings)

Raw and unprocessed agricultural, aquacultural, horticultural and forestry products

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does BioMar Group A/S have?

BioMar Group A/S has 5 U.S. trademarks filed with the USPTO. Of these, 3 registered, 1 abandoned.

What trademark classes does BioMar Group A/S file in?

BioMar Group A/S files trademarks across 2 Nice Classification classes. The most active classes are Class 31 (Natural Agricultural Products), Class 5 (Pharmaceuticals). Class 31 covers raw and unprocessed agricultural, aquacultural, horticultural and forestry products.

What are BioMar Group A/S's most well-known trademarks?

BioMar Group A/S's registered trademark portfolio includes well-known marks such as LARVIVA, SMARTCARE, and BLUE IMPACT. These are among 3 currently registered trademarks in the portfolio.

What is BioMar Group A/S's trademark registration success rate?

BioMar Group A/S has a 75% trademark registration rate, with 3 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.